1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Canagliflozin
Trade Name:
Invokana
Classification:
antihyperglycemic agent
sodium-glucose co-transporter 2 (SGLT2) inhibitor
ATC Class:
A10BX11 - canagliflozin
Status:
active
Notice of Compliance (yyyy/mm/dd):
2014/05/23
Date Marketed in Canada (yyyy/mm/dd):
2014/06/25
Presentation:
Tablet: 100 mg. DIN: 02425483
Tablet: 300 mg. DIN: 02425491
Comments:
Canagliflozin is an inhibitor of sodium-glucose-co-transporter 2 (SGLT2), which is expressed in the proximal renal tubules and is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Patients with diabetes have been shown to have elevated renal glucose reabsorption which can contribute to elevated blood glucose concentrations. Canagliflozin increases urinary glucose excretion and directly lowers plasma glucose independent of insulin.
Source:
Product monograph
Back to:
Drug Product Listings 
